Abstract：
OBJECTIVE: Acute radiation dermatitis (ARD) is a frequent adverse effect in patients with cancer undergoing radiotherapy (RT). The aim of this case series is to evaluate the effect of a novel skin barrier protectant in patients with ARD.
METHODS: The skin barrier protectant was used in four patients with different cancer types undergoing RT at two clinical sites. All patients received the standard institutional skincare alongside the novel skin barrier protectant. The skin reactions were evaluated by an RT nurse using the modified version of the Radiation Therapy Oncology Group criteria.
RESULTS: At the final RT session, three of four patients developed erythema with or without dry desquamation. One patient presented only a minor patchy moist wound. Overall, the pain and pruritus due to ARD was low or nonexistent. No adverse events related to the skin barrier protectant were reported.
CONCLUSIONS: This case series demonstrates the beneficial effects and safety of the novel skin barrier protectant in the management of ARD in patients with cancer of different etiologies. These results lay the foundation for future studies with larger, more homogeneous patient populations; a well-defined application scheme; and a stricter study design.
METHODS: The skin barrier protectant was used in four patients with different cancer types undergoing RT at two clinical sites. All patients received the standard institutional skincare alongside the novel skin barrier protectant. The skin reactions were evaluated by an RT nurse using the modified version of the Radiation Therapy Oncology Group criteria.
RESULTS: At the final RT session, three of four patients developed erythema with or without dry desquamation. One patient presented only a minor patchy moist wound. Overall, the pain and pruritus due to ARD was low or nonexistent. No adverse events related to the skin barrier protectant were reported.
CONCLUSIONS: This case series demonstrates the beneficial effects and safety of the novel skin barrier protectant in the management of ARD in patients with cancer of different etiologies. These results lay the foundation for future studies with larger, more homogeneous patient populations; a well-defined application scheme; and a stricter study design.
摘要：
目的：急性放射性皮炎（ARD）是接受放疗（RT）的癌症患者的常见不良反应。本病例系列的目的是评估新型皮肤屏障保护剂在ARD患者中的作用。
方法：将皮肤屏障保护剂用于在两个临床部位接受RT的4名不同类型癌症患者。所有患者都接受了标准的机构护肤以及新型皮肤屏障保护剂。RT护士使用放射治疗肿瘤学组标准的修改版本评估皮肤反应。
结果：在最后的RT会议上，四名患者中有三名出现有或没有干性脱屑的红斑。一名患者仅出现轻微的斑片状潮湿伤口。总的来说,ARD引起的疼痛和瘙痒较低或不存在.未报告与皮肤屏障保护剂相关的不良事件。
结论：本系列病例证明了新型皮肤屏障保护剂在不同病因癌症患者治疗ARD中的有益效果和安全性。这些结果为以后的研究奠定了基础,更同质的患者群体；定义明确的应用方案；和更严格的研究设计。
方法：将皮肤屏障保护剂用于在两个临床部位接受RT的4名不同类型癌症患者。所有患者都接受了标准的机构护肤以及新型皮肤屏障保护剂。RT护士使用放射治疗肿瘤学组标准的修改版本评估皮肤反应。
结果：在最后的RT会议上，四名患者中有三名出现有或没有干性脱屑的红斑。一名患者仅出现轻微的斑片状潮湿伤口。总的来说,ARD引起的疼痛和瘙痒较低或不存在.未报告与皮肤屏障保护剂相关的不良事件。
结论：本系列病例证明了新型皮肤屏障保护剂在不同病因癌症患者治疗ARD中的有益效果和安全性。这些结果为以后的研究奠定了基础,更同质的患者群体；定义明确的应用方案；和更严格的研究设计。
